Equillium (EQ) to Post Earnings on Thursday

Equillium (NASDAQ:EQ) is projected to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($0.05) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). On average, analysts expect Equillium to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Equillium Stock Performance

Shares of EQ stock opened at $2.19 on Tuesday. Equillium has a fifty-two week low of $0.76 and a fifty-two week high of $3.54. The stock has a 50 day simple moving average of $2.72 and a two-hundred day simple moving average of $2.21. The company has a market cap of $138.47 million, a P/E ratio of -6.84 and a beta of 1.83.

Insider Transactions at Equillium

In other Equillium news, insider Penny Tom sold 65,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $2.95, for a total transaction of $191,750.00. Following the completion of the sale, the insider directly owned 65,000 shares in the company, valued at $191,750. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stephen Connelly sold 200,000 shares of Equillium stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $3.16, for a total transaction of $632,000.00. Following the completion of the transaction, the insider directly owned 793,000 shares in the company, valued at approximately $2,505,880. The trade was a 20.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 406,392 shares of company stock worth $1,224,898. 17.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in EQ. Virtu Financial LLC raised its position in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after acquiring an additional 13,591 shares during the period. Millennium Management LLC purchased a new stake in shares of Equillium in the 3rd quarter worth $35,000. Royal Bank of Canada purchased a new stake in shares of Equillium in the 4th quarter worth $124,000. Persistent Asset Partners Ltd raised its holdings in Equillium by 35.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock worth $144,000 after purchasing an additional 24,132 shares during the period. Finally, Boothbay Fund Management LLC bought a new position in Equillium in the 3rd quarter worth $174,000. 27.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on EQ. Oppenheimer began coverage on shares of Equillium in a report on Thursday, April 23rd. They set an “outperform” rating and a $7.00 price target on the stock. B. Riley Financial assumed coverage on shares of Equillium in a research report on Thursday, April 16th. They set a “buy” rating and a $6.00 target price on the stock. Clear Str upgraded Equillium to a “strong-buy” rating in a research note on Tuesday, July 21st. Stifel Nicolaus set a $5.00 target price on Equillium in a report on Thursday, May 28th. Finally, Roth Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Equillium in a research report on Thursday, May 28th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Equillium has a consensus rating of “Moderate Buy” and an average target price of $7.57.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.